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Abstract
Widespread, repeated testing using rapid antigen tests to proactively detect asymptomatic SARS-CoV-2 infections has been 
a promising yet controversial topic during the COVID-19 pandemic. Concerns have been raised over whether currently 
authorized lateral flow tests are sufficiently sensitive and specific to detect enough infections to impact transmission whilst 
minimizing unnecessary isolation of false positives. These concerns have often been illustrated using simple, textbook cal-
culations of positivity rates and positive predictive value assuming fixed values for sensitivity, specificity and prevalence. 
However, we argue that evaluating repeated testing strategies requires the consideration of three additional factors: new 
infections continue to arise depending on the incidence rate, isolating positive individuals reduces prevalence in the tested 
population, and each infected individual is tested multiple times during their infection course. We provide a simple math-
ematical model with an online interface to illustrate how these three factors impact test positivity rates and the number of 
isolating individuals over time. These results highlight the potential pitfalls of using inappropriate textbook-style calculations 
to evaluate statistics arising from repeated testing strategies during an epidemic.
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From 8 March 2021, students in English secondary schools 
began routine asymptomatic testing for SARS-CoV-2 infec-
tion using rapid lateral flow tests (LFTs). Students were 
tested at school three times during the first two weeks after 
their return to the classroom and then given two tests per 
week to use at home. The strategy aimed to identify and 
prompt the isolation of infected students to keep SARS-
CoV-2 transmission within schools minimal.
Two primary concerns were raised over widespread LFT 
surveillance testing in schools. First, the observed test posi-
tivity rate from LFT testing was lower than SARS-CoV-2 
prevalence estimates from population-wide surveys [1, 2]. 
This raised the question of whether many infections were 
being missed due to inadequate LFT sensitivity. Second, 
as the prevalence of SARS-CoV-2 in school aged children 
was low and declining, it was argued that a high number of 
false positives results could lead to considerable unneces-
sary isolation for students and their class bubbles. These 
concerns have largely been illustrated using simple, textbook 
calculations that assume fixed numbers for test sensitivity, 
specificity and prevalence measured at a single point in time.
We argue that interpreting statistics from repeated sur-
veillance testing requires the consideration of three addi-
tional factors: (1) infection incidence changes over time, 
dictating not only prevalence but also the number of new 
infections to be detected, (2) isolating detected infections 
decreases prevalence in the tested population with each sub-
sequent testing round, and (3) test sensitivity is not a static 
value but varies over the course of an individual’s infection. 
Using a simple model of repeated LFT testing, we illus-
trate how these factors influence the test positivity rate and 
positive predictive value (PPV) of a given testing strategy, 
thereby dictating the number of incorrectly isolating indi-
viduals over time. Although the model is broadly based on 
testing in English secondary schools, these considerations 
are relevant for interpreting statistics from repeated testing 
strategies in general. The model is available to test under 
alternative assumptions in an accompanying online tool.
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The first observation from the model is that positiv-
ity rates under regular testing are lower than prevalence 
observed in random cross-sectional LFT/qPCR surveys. 
Although routine LFT screening initially returns the same 
percentage positive as a random cross-sectional survey, the 
number of true positives left to be detected is reduced with 
each testing round as true positives are detected, isolated 
and no longer retested. This effect may be counteracted by 
the incidence of new infections, but with a sufficiently high 
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faster than it can be replenished. As a result, the percent-
age of positive tests under a regular screening strategy sits 
between incidence and prevalence (Fig. 1a)—a low observed 
test positivity compared to cross-sectional surveillance is 
therefore expected under regular screening and should not 
be compared to prevalence estimates to evaluate the success 
of the strategy.
The second observation is that the removal of true infec-
tions from the tested population affects the proportion, 
but not absolute number, of false positive test results. The 
probability that a positive LFT represents a true infection is 
given by the PPV, which depends on the test specificity and 
prevalence of SARS-CoV-2. Although both LFTs and qPCR 
are highly specific (LFT specificity has been estimated at 
99.5% or higher [3, 4]), PPV will be low during periods of 
very low prevalence. Because prevalence in the test popula-
tion decreases with each testing round as true positives are 
detected and isolated, the PPV of the regular testing program 
declines over time, on top of any effect from changes in 
overall prevalence (Fig. 1b). Conversely, the negative predic-
tive value increases with each testing round (Supplementary 
Information Fig. S1).
It is important to distinguish the PPV from the false posi-
tive rate, which is independent of prevalence and given by 
the number of false positives divided by the number of tests 
performed on truly uninfected individuals [5]. While the 
PPV of the testing strategy may become low, the absolute 
number of false positives is constant and remains small in 
each testing round. This means that a relatively small num-
ber of individuals are incorrectly isolating at a given time 
(Fig. 1c, d), unless a large number of contacts, such as pupils 
from the same class, are also quarantined following detec-
tion of a single positive.
The final observation is that very few infections go com-
pletely undetected when individuals are routinely tested 
every three days, as at least one test day will likely coincide 
with a period of high viral load (Supplementary Informa-
tion Fig. S2). LFT sensitivity has been reported as a single 
value at 50.1% in the context of school testing, reflecting the 
overall positive percentage agreement (PPA) with qPCR for 
infected individuals tested on an unknown day post infection 
[3]. However, test sensitivity is not a single static value, but 
depends on the quantity of viral material within the host, 
which increases and then decreases over the course of an 
infection (Supplementary Information Fig. S3). When indi-
viduals are tested prospectively, infections that are missed 
due to low viral loads on the first test day are likely to have 
higher viral loads and corresponding increased sensitiv-
ity at the next test: the sensitivity of the overall strategy to 
detect an infection in at least one test is very high, even if the 
observed sensitivity from trials involving testing individuals 
once is low.
Overall, these observations demonstrate the challenges of 
interpreting positivity rates when repeatedly testing and iso-
lating individuals during periods of declining SARS-CoV-2 
prevalence. Simple calculations assuming fixed values for 
test characteristics and prevalence are useful for illustrative 
purposes but are insufficient to interpret statistics emerg-
ing from repeated testing programs during an epidemic. A 
related topic not discussed here is the choice of test char-
acteristics tailored to different public health purposes [6]. 
Here, we defined a true positive as any individual within 
21 days of infection, but we note that more stringent defini-
tions including only infectious or high viral load individuals 
will also impact the interpretation of LFT and qPCR positiv-
ity rates. Although the ability of sustained mass screening 
strategies, as carried out in English schools, to detect and 
isolate infected individuals is very high, the costs, benefits 
and risk of false negatives arising from confirmatory and 
test-to-release antigen or molecular testing will require 
ongoing evaluation.
Supplementary Information The online version contains supplemen-
tary material available at https:// doi. org/ 10. 1007/ s10654- 021- 00786-w.
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Fig. 1  Test positivity and positive predictive value decline alongside 
prevalence, but the number of false positives and subsequent isola-
tions are stable. Simulation uses a population of 1.5 million individ-
uals to match the number of secondary school pupils tested in their 
first week of return to school, with prevalence, test characteristics and 
test frequency chosen to broadly reflect the situation in England 7. 
True prevalence, defined as the prevalence of all individuals within 
21 days of infection, ranged from 2.29% on the first day of the strat-
egy to 0.153% on the last day. LFT specificity is set to 99.97% and 
qPCR specificity to 99.99%. Full simulation assumptions and parame-
ters are shown in the electronic supplementary material. The repeated 
screening strategy is initiated when true prevalence is at approxi-
mately 1.5% (vertical dashed lines). (A) Percentage of tests returning 
positive under random cross-sectional testing with LFT or qPCR and 
no isolation of positives or testing all individuals by LFT every three 
days with isolation of positives compared to true prevalence and inci-
dence. Note that daily incidence ranges from 6.33 to 0.405 infections 
per 10,000 people (Supplementary Information Fig. S4). Black dots 
show the observed test positivity from the 3-day LFT screening tests 
performed on that day. (B) Positive predictive value (PPV) of random 
cross-sectional testing with LFT or qPCR, or 3-day LFT screening 
with removal of positives. PPV ranged from 95.3% to 36.5% for the 
3-day LFT screening strategy. (C) Number of positives detected on 
each day of the 3-day LFT screening strategy. (D) Number of indi-
viduals in isolation over time under the 3-day LFT screening strategy, 
stratified by whether they were detected as a true or false positive
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